OUR STORY
ALBUPAD is a spin-off from a leading research center in biomedicine renowned for its strong focus on biomaterials, which still provides R&D support to Albupad innovation process.
Our founders are award-winning scientists committed to transforming patient care. They are supported by an experienced and multidisciplinary advisory board, with deep expertise in drug delivery, biomaterials and pharmacology – including clinicians and translational experts.
MEET THE TEAM
PharmD and PhD in Materials Chemistry, Eya Aloui is the founder and lead inventor of ALBUPAD’s technology. Her academic work, conducted at the Biomaterials & Bioengineering laboratory (UMR_S 1121 INSERM–University of Strasbourg–CNRS) and the 3Bio team at CAMB (UMR 7199 CNRS–University of Strasbourg), focused on the development of innovative protein-based materials using green chemistry approaches. Bridging science and entrepreneurship early on, she led the pre-maturation and maturation of the technology through projects supported by technology transfer programs (SATT Conectus), transforming academic research into a robust, application-ready platform. She then founded ALBUPAD to bring this breakthrough technology to the pharmaceutical market. She is a laureate of the prestigious i-PhD and i-Lab programs, recognizing both the scientific excellence and the innovation potential of her work. As CEO, she drives ALBUPAD’s strategic vision, R&D roadmap, industrial partnerships, and fundraising activities.
PhD in Physicochemistry of Biomaterials and co-founder of ALBUPAD, Jordan Beurton leads the company’s scientific and technical strategy as well as industrial development. He brings strong expertise in formulation development, analytical process development, and scale-up. He oversees the structuring of R&D activities (process, formulation, preclinical) and manages collaborations with CROs and CDMOs (including Synerlab and Aerial) to support the transition toward GMP-like processes. He also coordinates key partnerships and collaborative R&D projects with the Biomaterials & Bioengineering laboratory (UMR_S 1121 INSERM–University of Strasbourg–CNRS).
OUR SUPPORT NETWORK
ALBUPAD is backed by seasoned biopharmaceutical business development and financial experts, and benefits from a strong, well-established innovation ecosystem.
ACADEMIC PARTNERS
STRATEGIC PARTNERS
AWARDS
